Ainos (NASDAQ:AIMD) Major Shareholder Sells $99,820.00 in Stock

Ainos, Inc. (NASDAQ:AIMD) major shareholder Carbon Nano Technology Taiwan sold 46,000 shares of the stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $2.17, for a total transaction of $99,820.00. Following the completion of the transaction, the insider owned 989,925 shares in the company, valued at $2,148,137.25. This represents a 4.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Carbon Nano Technology Taiwan also recently made the following trade(s):

• On Friday, January 9th, Carbon Nano Technology Taiwan sold 431 shares of Ainos stock. The shares were sold at an average price of $1.86, for a total transaction of $801.66.
• On Thursday, January 8th, Carbon Nano Technology Taiwan sold 850 shares of Ainos stock. The stock was sold at an average price of $1.80, for a total value of $1,530.00.

Ainos Stock Down 14.9%

Shares of Ainos stock opened at $2.00 on Friday. Ainos, Inc. has a 12 month low of $1.61 and a 12 month high of $4.50. The business has a fifty day simple moving average of $1.99 and a 200 day simple moving average of $2.84. The company has a quick ratio of 2.67, a current ratio of 2.96 and a debt-to-equity ratio of 1.10. The stock has a market cap of $9.62 million, a PE ratio of -0.50 and a beta of 2.45.

Ainos (NASDAQ:AIMD) last issued its earnings results on Thursday, November 13th. The company reported ($0.64) earnings per share (EPS) for the quarter. The business had revenue of $0.00 million during the quarter.

Institutional Trading of Ainos

An institutional investor recently bought a new position in Ainos stock. Two Sigma Investments LP purchased a new stake in Ainos, Inc. (NASDAQ:AIMD) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 23,008 shares of the company’s stock, valued at approximately $80,000. Two Sigma Investments LP owned 0.48% of Ainos as of its most recent SEC filing.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Ainos in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

About Ainos

Ainos, Inc (NASDAQ: AIMD) is a clinical?stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI?401, is an inhaled formulation of ibuprofen in a dry powder format.